Adjust based on thirst, urine color, and activity level
Mann, University Hospital Erlangen, Friedrich Alexander University, Erlangen, Germany, and colleagues conducted the FLOW trial comprising participants with T2D and CKD who were stratified by baseline SGLT2i use (N = 550) or no use (N = 2,983) and randomized to semaglutide/placebo
Set phone alarms for your chosen injection day in your destination time zone
Reason #7 Underlying Medical Conditions or Medications Quick Answer Medical conditions like PCOS, hypothyroidism, and other hormonal imbalances can blunt semaglutide results
For many, continuing the medication even after reaching target weight will be necessary to maintain results, similar to managing a chronic condition like hypertension or diabetes